GlassScriptPhysician profile
Ibrahim I Dagher
NPI 1992238745
$6,266.28
in general payments reported to CMS, 2019-2025
16 companies · $3,404 in 2025
The $3,404 reported for 2025 was more than what 93% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $714 · 2020: $212 · 2022: $121 · 2023: $412 · 2024: $1,404 · 2025: $3,404.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,845 · Education: $225 · Honoraria: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,845.20 |
| Education | $224.66 |
| Honoraria | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,561.13 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $975.00 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Teva Pharmaceuticals USA, INC. | $711.52 | 2020-2025 | Uzedy, Austedo Xr |
| Neurocrine Biosciences, INC. | $611.57 | 2019-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $610.71 | 2024-2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $339.99 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $279.54 | 2024-2025 | Caplyta |
| Axsome Therapeutics, INC. | $272.30 | 2023-2025 | Auvelity |
| Abbvie INC. | $244.05 | 2024-2025 | |
| Idorsia Pharmaceuticals US INC | $224.70 | 2022-2023 | Quviviq |
| H2-Pharma, LLC | $150.00 | 2025 | |
| Lundbeck LLC | $144.38 | 2019-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $71.04 | 2023-2025 | Qelbree, Qelbree |
| Vanda Pharmaceuticals INC. | $23.70 | 2019 | |
| Corium, LLC | $23.33 | 2024 | Azstarys |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Luye Pharma (USA) LTD. | $23.32 | 2025 | Erzofri Extended-Release |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ibrahim Dagher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.